Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Antiphospholipid Syndrome with Secondary Thrombocytopenia
NCT05199909Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in antiphospholipid syndrome (APS), Thrombocytopenia, sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jan 2022; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
antiphospholipid syndrome (APS)Thrombocytopenia
Beyond the preview
Go deeper on NCT05199909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05199909.